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Background: Proper evaluation of new diagnostic tests is required to reduce overutilization and to limit potential
negative health effects and costs related to testing. A decision analytic modelling approach may be worthwhile
when a diagnostic randomized controlled trial is not feasible. We demonstrate this by assessing the
cost-effectiveness of modified transesophageal echocardiography (TEE) compared with manual palpation for the
detection of atherosclerosis in the ascending aorta.
Methods: Based on a previous diagnostic accuracy study, actual Dutch reimbursement data, and evidence from
literature we developed a Markov decision analytic model. Cost-effectiveness of modified TEE was assessed for a life
time horizon and a health care perspective. Prevalence rates of atherosclerosis were age-dependent and low as
well as high rates were applied. Probabilistic sensitivity analysis was applied.
Results: The model synthesized all available evidence on the risk of stroke in cardiac surgery patients. The modified
TEE strategy consistently resulted in more adapted surgical procedures and, hence, a lower risk of stroke and a
slightly higher number of life-years. With 10% prevalence of atherosclerosis the incremental cost-effectiveness ratio
was €4,651 and €481 per quality-adjusted life year in 55-year-old men and women, respectively. In all patients aged
65 years or older the modified TEE strategy was cost saving and resulted in additional health benefits.
Conclusions: Decision analytic modelling to assess the cost-effectiveness of a new diagnostic test based on
characteristics, costs and effects of the test itself and of the subsequent treatment options is both feasible and
valuable. Our case study on modified TEE suggests that it may reduce the risk of stroke in cardiac surgery patients
older than 55 years at acceptable cost-effectiveness levels.
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The number of diagnostics tests and (bio)markers avail-
able in medical practice has been increasing rapidly over
the past decades and is likely to increase even further
given the quest for stratified and personalized medicine.
Consequently, there is growing concern about the overuti-
lization of diagnostic tests and markers, the potential
negative health consequences due to over testing, and the
steeply rising costs for diagnostic testing [1,2]. To avoid
these problems proper evaluation of the downstream* Correspondence: h.koffijberg@umcutrecht.nl
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reproduction in any medium, provided the orconsequences or benefits, in terms of improved decision
making and patient outcomes, as well as on the cost-
benefits of diagnostic testing, is required [3-11]. However,
the evaluation of diagnostic tests and markers typically
stops after quantifying the accuracy of the test or marker
as compared to the prevailing reference standard [4-6,8-
11]. The consequences of diagnostic testing strategies may
be quantified comprehensively in randomized clinical
trials (RCT). However, RCTs of diagnostic strategies are
not always recommended since they are often too costly
and time consuming. They are also considered less feasible
given the large number of available diagnostic strategies
that can be compared and the consequently required
number of patients [4,10,12-15]. Moreover, the limitedral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of long-term outcomes or risks related to testing (e.g. radi-
ation risk due to imaging tests) and technological evolu-
tion of diagnostics may render the RCT results quickly
out-dated. Finally, the overwhelming number of new tests
and markers entering the market would require a huge
number of diagnostic RCTs for which there may not even
be enough patients to recruit. These limitations are also
apparent from the low number of such diagnostic (test-
treatment) RCTs in current literature [15].
Decision analytic and cost-effectiveness modelling is a
valid alternative to diagnostic RCTs to quantify the effects
of testing on long terms outcomes and costs. Suitable
models can synthesize the evidence from different sources,
including pre-clinical studies (e.g. evidence on risks), diag-
nostic test accuracy studies, and therapeutic intervention
studies (e.g. evidence on outcomes) [4,10,16-18]. Subse-
quently, the life course of hypothetical individuals can be
simulated while tracking risk factors, complications,
quality of life, and costs, to assess the incremental cost-
effectiveness of a new diagnostic strategy [17,19-21].
In this paper we illustrate decision analytic modelling
using an empirical study to assess the long term health
effects and cost-effectiveness of using a new diagnostic
test, modified transesophageal echocardiography (TEE) as
compared to care as usual in patients undergoing cardiac
surgery. This test is used to detect aortic atherosclerosis as
early as possible in order to prevent embolic stroke caused
by emboli merging from the atherosclerotic ascending
aorta during surgery. Rather than discussing the potential
value of decision analytic modelling in general we show
that the cost-effectiveness of modified TEE can be esti-
mated without performing a diagnostic RCT and present
the elements and results of our analysis.
Methods
Description of the example study
The incidence of ischemic stroke after cardiac surgery is
about 3%, accounting for 10–20% of postoperative deaths
[22-25]. As the prevalence of atherosclerosis increases
sharply with age from 10% in patients aged 50–60 years to
at least 35% in patients older than 75 years, the post-
cardiac-surgery stroke rate also increases to 7% in older
patients [26,27]. Post-operative stroke is often caused by
emboli from dislodged atherosclerotic plaques in the
ascending aorta, when it is cannulated or clamped
[22,23,28-30]. Knowing the presence and extent of athero-
sclerosis prior to sternotomy allows changes in surgical
strategy reducing or avoiding manipulation of the ascend-
ing aorta, and may therefore reduce the post-operative
risk of embolic stroke. Hence, rapid and accurate diagno-
sis of atherosclerosis in the ascending aorta may result in
a decreasing number of ischemic strokes after cardiac sur-
gery caused by emboli.We compared the modified transesophageal echocardi-
ography (TEE) strategy with the manual palpation strat-
egy. Manual palpation is still the most commonly used
method for assessing atherosclerosis in the ascending
aorta although it is not very sensitive and may be hazard-
ous, i.e. it may dislodge vulnerable atherosclerotic plaques,
which in turn may cause stroke, and it can only be used
after sternotomy [31]. The modified TEE method was
introduced to enhance conventional TEE by visualizing
the distal part of the ascending aorta before incision, using
an intra-tracheal balloon-catheter (the A-View catheter,
Cordatec Inc. Zoersel, Belgium) to create an ultrasound
conducting window [32,33]. For both methods epiaortic
ultrasound scanning (EU) was used to assess diagnostic
accuracy and potential impact on clinical management.
Epiaortic ultrasound scanning may be considered the gold
standard for detecting ascending aorta atherosclerosis but
cannot be applied prior to surgery and is not available in
all medical centres [34,35].
Model description
We used a Markov decision analytic model to assess the
differences in long term health benefits and costs of both
strategies [19]. In the modified TEE strategy surgery could
be adapted due to the presence of atherosclerosis detected
pre-sternotomy with modified TEE. In the manual palpa-
tion strategy surgery could be adapted due to the presence
of atherosclerosis detected with manual palpation after
sternotomy.
The decision analytic part of our model (first part) esti-
mated the fraction of cardiac patients that experienced no
complications (no stroke), a non-fatal stroke, a fatal
stroke, and death due to other causes, separately for each
diagnostic strategy (Figure 1A). The outcomes served as
input for the Markov model (second part).
Markov models are useful when events can occur at
various points in time and with varying probabilities [36].
In a Markov model hypothetical individuals reside in pre-
defined health states and can move from one health state
to another in fixed time intervals. We defined the health
states ‘post-surgery – no complications’, ‘post-surgery –
post stroke’, and ‘dead’, and individuals started in these
health states based on the outcome of the decision analytic
part of our model (Figure 1B). After a fatal stroke or death
due to other causes individuals started, and remained, in
the ‘dead’ state. Individuals in the ‘post cardiac surgery –
no complications’ state and the ‘post cardiac surgery – post
stroke’ state could die from causes unrelated to the surgical
procedure, and then move to the ‘dead’ state. Here, the risk
of death was based on age and gender specific all-cause
Dutch mortality rates (Statistics Netherlands, CBS), apart
from the first five years after surgery in which the mortality
risk was increased, reflecting the mortality experience of
cardiac surgery patients.
Figure 1 Visualization of the decision analytic part of the model for the manual palpation strategy [A], and the ensuing Markov part of
the model [B]. The structure of the model for the modified TEE strategy is similar.
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and costs to each health state in the Markov part of
our model, and also accounted for the costs of diag-
nosis and adaptation in the decision analytic part of
our model.The prevalence of atherosclerosis and the risk of stroke
We varied the prevalence of atherosclerosis in our model,
allowing it to increase with age, and performed separate
analyses for men and women, as accurate data on the age
and gender specific prevalence of atherosclerosis is lacking.
Table 1 The baseline values for model parameters
Input parameter Value* Range$ Distribution Source
Probability of early death (within 30 days) EuroSCORE risk equation [37]
Probability death is due to fatal stroke event 13.2% 7.5 – 20.2% Beta(14,92) [25]
Probability that a stroke event is not fatal 80.8% 75.3 – 85.8% Beta(173,41) [38]
Probability that stroke is caused by emboli 71.0% 63.3 – 77.8% Beta(107,44) [38]
Manual palpation: sensitivity 31% 22 – 40% Beta(33,73) [31]
Manual palpation: specificity 98% 96 – 100% Beta(179,4) [31]
Modified TEE: sensitivity 97% 94 – 100% Beta(124,4) [39]
Modified TEE: specificity 80% 74 – 85% Beta(173,44) [39]
Risk reduction of post-operative stroke due to adaptations
when applying the modified TEE
0.46 0.196 – 0.910 LogNormal (−0.864,
0.392)
[25]†
Probability of a major adaptation of surgery given a patient with
atherosclerosis
2.7% 2.3 – 3.1% Beta(163,5888) [40]
Risk of death (year 1–2 post-surgery): age < 61 years 1.18% 0.82 – 1.42% Uniform [41] ‡
Risk of death (year 1–5 post-surgery): age 61–70 years 2.33% 1.95 – 2.71% Uniform [41] ‡
Risk of death (year 1–5 post-surgery): age > 70 years 4.35% 3.49 – 5.24% Uniform [41] ‡
Utility of the ‘Post Stroke’ health state 0.439 0.186 – 0.653 Triangular [42]^
Utility of the ‘No complications’ health state 1 - - Default
Cost of death (Euros) 2,736 1,368 – 5,471 Uniform Expert opinion
[43]
Diagnostic cost of modified TEE tool (Euros) 212 184 –243 Gamma Manufacturer
Cost of fatal stroke event (Euros) 2,736 1,368 – 5,471 Uniform #
Discount rate for costs 4.0% - - Dutch guidelines
Discount rate for effects 1.5% - - Dutch guidelines
The baseline values that were used as input parameters for the model, along with their range and distribution (if applicable).
* All costs were recalculated to 2012 euros.
$ Range concerns the full range for uniform distributions and 95% confidence intervals for other distribution types.
# The cost of a fatal stroke was assumed equal to the cost of death, as the costs of additional medical care delivered to stroke patients prior to death is already
incorporated in the costs of surgery (Additional file 1).
† This risk reduction was based on the comparison of two groups in the original article: group C (13 strokes in 690 patients) versus group A (12 strokes in
268 patients).
‡ Values were recalculated from the actuarial survival curves by age in the source material and concern annual mortality risks applied in the first five years after
cardiac surgery.
^ Estimates of the utility of patients after major stroke vary widely therefore a large range was used (min = 0.11, max = 0.71, most likely value = 0.50, resulting in
an expected value of 0.439).
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(55, 65, 75 year old patients), and two estimates of the
prevalence of distal ascending aorta atherosclerosis across
age categories. Low prevalence rates were 10%, 20% and
40% at age 55, 65 and 75 years respectively, and high
prevalence rates 15%, 30% and 50% respectively. As
patients can die from a number of complications arising
during or after cardiac surgery, we separated fatal stroke
events from fatal non-stroke events. Roughly 15% of all
cardiac mortality was attributed to fatal strokes [25]. How-
ever, not every stroke needs to be fatal: patients can also
experience non-fatal strokes. We included a 38% probabil-
ity that a stroke is fatal, giving a 62% probability that a
stroke is non-fatal [25]. Finally, not all strokes are actually
caused by emboli merging from the atherosclerotic
ascending aorta, some have other causes and cannot,
therefore, be prevented by reducing manipulation of theascending aorta. In our model, 70% of all strokes were
assumed to be embolic and thereby potentially preventable
through changes in surgical strategy after detection of
atherosclerosis, whereas the remaining 30% was assumed
to have other origins.
Model assumptions
The following assumptions were required for the cost-
effectiveness analysis:
1. The beneficial effect from surgical adaptation was
similar for minor and for major adaptations (a relative
risk of embolic stroke of 0.46 (95%CI: 0.196- 0.910)).
However, major adaptations increased surgical costs,
whereas minor adaptations (e.g. relocation of clamps)
did not. Also, in patients with a false positive test result
only minor adaptations may be performed, as any
Table 2 Expected probabilities of surgical adaptation and stroke
Subgroup Manual palpation strategy Modified TEE strategy















Risk of stroke Life-years
after
surgery
non-fatal fatal non-fatal fatal
1 Men 55 yr 10% 1.04% 3.03% 0.08% 1.01% 0.24% 23.06 9.43% 0.26% 0.84% 0.23% `23.10
2 Men 55 yr 15% 1.08% 4.54% 0.13% 1.04% 0.24% 23.05 14.14% 0.39% 0.86% 0.23% 23.10
3 Women 55 yr 10% 1.41% 3.04% 0.08% 1.36% 0.32% 26.09 9.43% 0.26% 1.14% 0.31% 26.16
4 Women 55 yr 15% 1.46% 4.54% 0.13% 1.40% 0.33% 26.08 14.14% 0.39% 1.16% 0.31% 26.15
5 Men 65 yr 20% 1.61% 6.07% 0.17% 1.53% 0.36% 15.17 18.84% 0.52% 1.25% 0.33% 15.22
6 Men 65 yr 30% 1.71% 9.10% 0.25% 1.61% 0.38% 15.15 28.29% 0.78% 1.29% 0.33% 15.20
7 Women 65 yr 20% 2.14% 6.06% 0.17% 2.05% 0.48% 17.49 18.84% 0.52% 1.67% 0.44% 17.56
8 Women 65 yr 30% 2.28% 9.10% 0.25% 2.15% 0.50% 17.44 28.27% 0.78% 1.71% 0.44% 17.53
9 Men 75 yr 40% 3.18% 12.15% 0.34% 2.94% 0.69% 8.73 37.72% 1.04% 2.31% 0.59% 8.80
10 Men 75 yr 50% 3.36% 15.13% 0.42% 3.10% 0.72% 8.70 47.13% 1.31% 2.39% 0.60% 8.77
11 Women 75 yr 40% 4.13% 12.13% 0.34% 3.83% 0.90% 10.44 37.70% 1.04% 3.02% 0.77% 10.55
12 Women 75 yr 50% 4.34% 15.21% 0.42% 4.02% 0.94% 10.40 47.11% 1.31% 3.09% 0.78% 10.53
The probabilities and life-years observed from the model. For both strategies the observed chance of adaptation of the surgical procedure is shown, the observed risk of stroke and the expected number of life-years
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incorrect test outcome, and to be aborted as a result.
2. To quantify the expected peri-operative mortality of
patients in our model correctly for both strategies, all
patients with atherosclerosis in the ascending aorta
had the risk factor extra-cardiac arteriopathy as
defined in the EuroSCORE risk equation.
Consequently, patients with atherosclerosis in the
ascending aorta had a higher risk of early mortality
than patients without atherosclerosis.
3. The impact of increasing age on quality of life of
individuals was assumed to similar for healthy
individuals and individuals surviving a stroke. The
utility of healthy individuals was therefore set to 1
and the impact of stroke was defined as a reduction
in utility from 1 to 0.439, on average.
Cost-effectiveness analysis
We defined two baseline groups: 65-year old men and
65-year old women, both with a prevalence of 20% athero-
sclerosis, because these groups contain the largest number
of patients seen in clinical practice. For each of the 12 sub-
groups defined, a hypothetical cohort of 10,000 patients
was simulated and the individual pathways of the patients
were determined, tracking events, costs, and quality of life,
for both diagnostic strategies. Average results were then
calculated for each hypothetical cohort. A life time hori-
zon was used, that is, simulation stopped when all patients
had moved to the ‘dead’ state, with time intervals (cycles)
of one year. We applied a health care perspective. Costs
were estimated in euros (1 euro = 1.28 US$, September 10
2012). Costs were discounted with 4.0% and effects withTable 3 Expected costs and effects for the predefined patient
Subgroup Manual palpation strategy






1 Men 55 yr 10% 25,896 14.31
2 Men 55 yr 15% 25,936 14.31
3 Women 55 yr 10% 25,984 15.34
4 Women 55 yr 15% 26,012 15.33
5 Men 65 yr 20% 26,589 10.75
6 Men 65 yr 30% 26,671 10.74
7 Women 65 yr 20% 26,720 11.83
8 Women 65 yr 30% 26,815 11.80
9 Men 75 yr 40% 27,629 7.01
10 Men 75 yr 50% 27,733 6.99
11 Women 75 yr 40% 28,563 8.10
12 Women 75 yr 50% 28,719 8.08
Cost and effect outcomes for each of the 12 predefined patient subgroups (see tex
incremental costs and effects and the incremental cost-effectiveness ratio (ICER).
* In this scenario the modified TEE strategy dominated the manual palpation strate1.5% according to Dutch guidelines. Based on the difference
in health benefits and costs we calculated the incremental
cost-effectiveness ratio (ICER). Probabilistic sensitivity
analysis was performed by Monte Carlo simulation, and
5,000 simulations were performed to account for parameter
uncertainty based on the distributions defined in Table 1.
All simulations were performed with TreeAge Pro 2011
software (Williamstown, MA, USA).
Results
Pre-existing evidence on the accuracy of the two
diagnostic strategies
For manual palpation we found a sensitivity of 31% (95%
CI: 22–40%) and a specificity of 98% (95%CI: 96–100%)
when compared with EU [31]. For modified TEE a crude
sensitivity of 97% (95%CI: 94–100%) and specificity of 80%
(95%CI: 74–85%) has been reported [39]. These estimates
were used in the model and relate to severe atheroma
which, when observed, would require adaptation of the
surgical procedure (Table 1). For both diagnostic strategies
false positive results could result in minor adaptations,
and false negative results caused a lack of adaptations
resulting in increased risk of embolic stroke.
Expected early mortality in cardiac surgical patients
We used the logistic version of the validated EuroSCORE
risk equation (comparable with the STS database) to
predict early (within 30 days) mortality of the patients
in our model [37,44,45]. The prevalence of the risk fac-
tors included in the EuroSCORE was derived from the
literature [45]. The risks predicted by the EuroSCORE
equation are substantially higher than currently observedsubgroups
















25,943 14.32 47 0.01 4,651
25,970 14.32 34 0.01 3,376
25,993 15.36 10 0.02 481
26,009 15.36 −3 0.03 −103*
26,581 10.77 −8 0.02 −420*
26,639 10.76 −32 0.02 −1,603*
26,662 11.86 −58 0.03 −1,946*
26,722 11.84 −93 0.04 −2,318*
27,479 7.04 −149 0.03 −4,973*
27,547 7.03 −186 0.04 −4,648*
28,182 8.15 −380 0.05 −7,608*
28,264 8.14 −455 0.06 −7,579*
t). For both strategies the costs and effects are given, as well as the
gy.
A: Incremental cost-effectiveness planewith
results for 55-year-old patients
B: Incremental cost-effectiveness plane with
results for 65-year-old patients
C: Incremental cost-effectiveness plane with
results for 75-year-old patients
Figure 2 (See legend on next page.)
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Figure 2 The cost-effectiveness plane with incremental costs and effects for 55-year old patients [A], 65-year old patients [B], and
75-year old patients [C]. These figures show the incremental effects (x-axis) and incremental costs (y-axis) of the modified TEE strategy. Each of
the 12 subgroups is visualized by an ellipsoid that represents the combined bivariate 95% confidence interval (CI) for incremental costs and
effects, and a symbol denoting the mean incremental costs and effects. The scales of the axes in Figures 2A-C are not similar, as the range of
incremental costs and effects increases with patient age.
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risks for our cohort of patients by 71%, the reduction
found in a large study on fast-track anaesthesia in cardiac
surgery [41,46].
Impact of diagnostic tests on surgical management, costs,
and the risk of embolic stroke
In the model, application of the modified TEE method
was expected to result in major adaptations in 2.7%
(95%CI: 2.3-3.1%) of all patients with detected athero-
sclerosis, similar to the influence of EU on intraopera-
tive surgical management [40]. Half of these adaptations
were in patients undergoing coronary artery bypass
grafting (CABG) or single valve surgery procedure, and
half in complex CABG (> 2 arterial grafts), CABG +
single valve or double valve procedure. The adaptations
all consisted of ascending aorta replacement with
CABG. On patient level, the mean cost of surgery without
adaptation equals €15,628, and of surgery with major
adaptation €23,886. However, major adaptations occur
only in 2.7% of all patients with atherosclerosis, rendering
the overall ‘weighted’ mean costs rather similar, i.e.
€15,628 without adaptation and €15,842 with the occa-
sional major adaptation (see Additional file 1). In both
strategies the detection of atherosclerosis in the remaining
100–2.7% = 97.3% of patients with atherosclerosis resulted
in minor surgical adaptations, without cost conse-
quences, such as changing the cannulation site and
changing the aortic clamping site. The cost of the
modified TEE intervention itself was relatively small
(€212,-), as the balloon-catheter is made from inexpen-
sive materials, and the modified TEE imaging proced-
ure takes, on average, only 4.5 minutes to perform
[33]. Finally, surgical adaptation was estimated to incur
a relative risk of post-operative embolic stroke of 0.46
(95%CI: 0.196-0.910) [25]. Details on costs of cardiac
procedures, non-fatal strokes, and potential major
changes in surgical procedures are provided in the
Additional file 1.
Cost-effectiveness outcomes
Table 2 presents the intermediate outcomes of the ana-
lysis, the predicted mortality risk, the risk of stroke, the
probability of adaptation, and the expected number of
life years after surgery. As expected, for both the manual
palpation strategy and the modified TEE strategy more
adaptation occurred with increasing prevalence ofatherosclerosis (Table 2). The risk of fatal and non-fatal
stroke events also increased with this prevalence and
with age, for both strategies. The number of life-years
after cardiac surgery decreased rapidly with patient age,
but only slightly with increasing prevalence of athero-
sclerosis, for both strategies. The risk of stroke was
higher in women than in men, as female sex is a risk
factor in the EuroSCORE risk equation. However, the
life-expectancy after surgery was still higher among
women. For all patient subgroups, the modified TEE
strategy consistently resulted in a larger number of
adapted procedures and, consequently, in a lower risk of
stroke and a slightly higher number of life-years.
For both strategies costs increased and health effects
decreased with increasing patient age, whereas increasing
prevalence of atherosclerosis had very limited influence
(Table 3). In our main scenario concerning 65 year old
men with 20% atherosclerosis manual palpation resulted
in costs of € 26,589 to gain 10.75 Quality-adjusted life-
years (QALYs), and modified TEE resulted in costs of €
26,581 to gain 10.77 QALYs. In the corresponding scenario
for women, costs and effects were € 26,720 and 11.83
QALYs for manual palpation and € 26,662 and 11.86
QALYs for modified TEE, respectively. The modified TEE
strategy was slightly more expensive in 55-year-old patients,
i.e. subgroups 1–3, and just cost-saving in 65-year-old
patients (Table 3). In 75-year-old patients modified TEE
offered substantial cost-savings. Cost-savings were higher
in women than in men. Furthermore, the modified TEE
strategy resulted in small health gains, increasing with age,
in all subgroups. Accordingly, the incremental cost-
effectiveness ratio (ICER) was positive in subgroup 1–3,
indicating additional health at additional cost, with a max-
imum ICER of €4,651 per QALY. In all other subgroups
the ICER was negative indicating additional health at
reduced cost. Here the modified TEE strategy dominated
the manual palpation strategy.
Figures 2A-C depict the uncertainty surrounding the
cost-effectiveness results shown in Table 3. In these fig-
ures the ellipsoids indicate the 95% confidence regions for
incremental cost and effects, for different subgroups of
patients, based on the results from the probabilistic sensi-
tivity analysis. In all figures the largest proportion of the
ellipsoids is located either the north-eastern or south-
eastern quadrants of the plane, indicating that the modi-
fied TEE is expected to result in health gain. To some







Figure 3 (See legend on next page.)
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Figure 3 Cost-effectiveness acceptability curves indicating the probability that the modified TEE strategy is cost-effective for 55-year
old patients [A], 65-year old patients [B], and 75-year old patients [C], as function of a range of cost-effectiveness threshold values.
The intersections of the curves with the vertical axis indicate the probability that the modified TEE strategy is cost-saving and results in health
gain, i.e. the probability that the cost-effectiveness is still acceptable even if a decision-maker is unwilling to pay anything for additional health
gain. The y-axis of Figure 3C was adjusted for visual clarity.
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outcomes for the modified TEE strategy. Comparing
men and women in Figures 2A-C it appeared that the
uncertainty was consistently larger for women than for
men, and increased with the prevalence of atheroscler-
osis and age. In addition, larger proportions of the ellip-
soids were located in the south-eastern quadrant. Thus,
the probability of the modified TEE strategy resulting in
cost saving and health gain increased although the exact
cost-saving and health gain became more uncertain.
Figures 3A-C shows cost-effectiveness acceptability curves
indicating the probability that the cost-effectiveness of the
modified TEE strategy would be acceptable for various cost-
effectiveness threshold (CET) values [47]. In Figures 3A-C
the intersections of the curves with the vertical axis indi-
cate the probability that the modified TEE strategy is cost-
saving and results in health gain, i.e. the probability that
the cost-effectiveness is still acceptable even if a decision-
maker is unwilling to pay anything for additional health
gain. Figure 3A shows that for 55-year-old patients this
probability ranged from 27% for men (prevalence athero-
sclerosis 10%) to 46% for women (prevalence atheroscler-
osis 15%). Figure 3B shows that for 65-year-old patients
this ranged from 46% for men (prevalence atherosclerosis
20%) to 66% for women (prevalence atherosclerosis 30%),
and for 75-year-old patients this probability ranged from
72% for men (prevalence atherosclerosis 40%) to 89% for
women (prevalence atherosclerosis 50%) (Figure 3C).
Considering a cost-effectiveness threshold of €20,000/
QALY as applied in The Netherlands, the probability that
modified TEE has acceptable cost-effectiveness is at least
77% for 55-year-old patients, at least 82% for 65-year-old
patients, and at least 90% for 75-year-old patients.
Discussion
In this paper we demonstrated the value of a comprehen-
sive decision analytic approach in a specific case study on
the prevention of post-operative embolic stroke in cardiac
surgery patients using different diagnostic test strategies.
With respect to our case study it has been shown previ-
ously that the modified TEE strategy allows imaging of the
atherosclerosis of the distal part of the ascending aorta
without severe and unexpected adverse effects [33]. Here
we find that the cost-effectiveness of the modified TEE
strategy compared with the manual palpation strategy var-
ies with patient age and gender, and with the prevalence
of atherosclerosis of the ascending aorta. Nevertheless,our results indicate that, in comparison with manual pal-
pation, the modified TEE strategy is expected to be cost-
saving and beneficial in all patients undergoing cardiac
surgery from the age of 65 years, also for low prevalence
rates of atherosclerosis. In patients 55 to 65 year old, how-
ever, the modified TEE strategy is expected to result in
small health benefits at very low costs, with a probability
of acceptable cost-effectiveness of >77% given the Dutch
threshold of €20,000/QALY.
Limitations of the case study analysis
Our model has certain limitations. First, to obtain an
estimate of the risk of death in patients with athero-
sclerosis in the ascending aorta after cardiac surgery we
used the increased risk of patients with arteriopathy as
based on the EuroSCORE. This assumption was neces-
sary because accurate evidence on the true excess risk
of death due to atherosclerosis in the ascending aorta
when undergoing cardiac surgery is lacking. Second,
there are no clear estimates of the prevalence of athero-
sclerosis in the ascending aorta in patients undergoing
cardiac surgery, certainly not as a function of patient
age. We resolved this issue by defining 12 different
patient subgroups with two prevalence rates per age
category. We found that the cost-effectiveness results
were rather similar for both low and high prevalence
rates of atherosclerosis per age category. Finally, the
incidence of embolic stroke increases with the complex-
ity of the surgical technique (maximum for combined
cardiac surgery and carotid endarterectomy procedures,
followed by surgery of the thoracic aorta and combined
valve and CABG surgery). However, evidence on the risk
of embolic stroke per surgical technique is lacking and
could therefore not be included in the analysis.
In the past two decades, diagnostic research method-
ology has progressed rapidly and in many directions,
but important challenges remain [48]. As diagnostic
RCTs to assess the long term effects of a new diagnostic
test, marker or strategy are often inefficient, infeasible
or too time consuming [4,10,12-15], decision analytic
and cost-effectiveness modelling can be a valuable alter-
native. Such approach may synthesize all available evi-
dence to provide insight into the effects of diagnostic
strategies, through downstream clinical management,
on patient outcomes and costs-effectiveness, both short
and long term. Examples of decision analytic models
used in cost-effectiveness analysis of diagnostic tests
Koffijberg et al. BMC Medical Research Methodology 2013, 13:12 Page 11 of 12
http://www.biomedcentral.com/1471-2288/13/12can be found in the literature, but are often limited in
their approach [49,50]. For example, they do not include
and synthesize relevant evidence on all possible diag-
nostic pathways, or focus only on short term conse-
quences, or perform only limited sensitivity analysis.
Cost-effectiveness models for evaluating diagnostic
tests will, in general, be more complex and require more
evidence, than cost-effectiveness models for evaluating
therapeutic interventions. However, we showed that
cost-effectiveness modelling of diagnostics tests is feas-
ible and can rapidly, at relatively low costs, provide
insights into the value of the use or introduction of a
new test or marker in terms of improved patient out-
comes. Moreover, models can be readily updated when
new evidence – e.g. on new treatments or new tests –
becomes available. Furthermore, model-based methods
can be used to determine whether a diagnostic RCT may
still be worthwhile to conduct and in which specific
patient groups, to optimize RCT design [19,51].Conclusion
Our analysis demonstrates how to use a decision analytic
and cost-effectiveness modelling approach to assess the
long term cost-effectiveness of a new diagnostic test,
marker or strategy - as compared to existing tests or
strategies - without doing a formal RCT. The approach
combines evidence on the costs and direct risks of the
test from early clinical studies, on the performance of
the test as compared to the existing reference standard
from test accuracy studies, and evidence on the effects
of subsequent treatments as obtained from treatment
follow-up studies. Our case study suggests that modified
transesophageal echocardiography may reduce the risk
of embolic stroke in cardiac surgery patients older than
55 years at acceptable cost-effectiveness levels.
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